Cargando…

Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer

Background: trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Silva-Oliveira, Rita, Pereira, Filipa Ferreira, Petronilho, Sara, Martins, Ana Teresa, Lameirinhas, Ana, Constâncio, Vera, Caldas-Ribeiro, Inês, Salta, Sofia, Lopes, Paula, Antunes, Luís, Castro, Fernando, de Sousa, Susana Palma, Henrique, Rui, Jerónimo, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761245/
https://www.ncbi.nlm.nih.gov/pubmed/33276477
http://dx.doi.org/10.3390/jcm9123911
_version_ 1783627523336175616
author Silva-Oliveira, Rita
Pereira, Filipa Ferreira
Petronilho, Sara
Martins, Ana Teresa
Lameirinhas, Ana
Constâncio, Vera
Caldas-Ribeiro, Inês
Salta, Sofia
Lopes, Paula
Antunes, Luís
Castro, Fernando
de Sousa, Susana Palma
Henrique, Rui
Jerónimo, Carmen
author_facet Silva-Oliveira, Rita
Pereira, Filipa Ferreira
Petronilho, Sara
Martins, Ana Teresa
Lameirinhas, Ana
Constâncio, Vera
Caldas-Ribeiro, Inês
Salta, Sofia
Lopes, Paula
Antunes, Luís
Castro, Fernando
de Sousa, Susana Palma
Henrique, Rui
Jerónimo, Carmen
author_sort Silva-Oliveira, Rita
collection PubMed
description Background: trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2+ patients do not respond to trastuzumab, new biomarkers of prognosis and prediction are warranted to allow a better patient stratification. Annexin A1 (ANXA1) was previously reported to contribute to trastuzumab resistance through AKT activation. An association between adenine thymine-rich interactive domain 1A (ARID1A) loss and ANXA1 upregulation was also previously suggested by others. Methods: in this study, we examined tissue samples from 215 HER-2+ breast cancer patients to investigate the value of ARID1A and ANXA1 protein levels in trastuzumab response prediction and patient outcome. Expression of ARID1A and ANXA1 were assessed by immunohistochemistry. Results: contrary to what was expected, no inverse association was found between ARID1A and ANXA1 expression. HER-2+ (non-luminal) tumours displayed higher ANXA1 expression than luminal B-like (HER-2+) tumours. Concerning trastuzumab resistance, ARID1A and ANXA1 proteins did not demonstrate predictive value as biomarkers. Nevertheless, an association was depicted between ANXA1 expression and breast cancer mortality and relapse. Conclusions: overall, our results suggest that ANXA1 may be a useful prognostic marker in HER-2+ patients. Additionally, its ability to discriminate between HER-2+ (non-luminal) and luminal B-like (HER-2+) patients might assist in patient stratification regarding treatment strategy.
format Online
Article
Text
id pubmed-7761245
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77612452020-12-26 Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer Silva-Oliveira, Rita Pereira, Filipa Ferreira Petronilho, Sara Martins, Ana Teresa Lameirinhas, Ana Constâncio, Vera Caldas-Ribeiro, Inês Salta, Sofia Lopes, Paula Antunes, Luís Castro, Fernando de Sousa, Susana Palma Henrique, Rui Jerónimo, Carmen J Clin Med Article Background: trastuzumab is considered the standard of care for human epidermal growth factor receptor-2 (HER-2+) breast cancer patients. Regardless of the benefits of its use, many early-stage patients eventually recur, and usually, the disease progresses within a year. Since about half of the HER-2+ patients do not respond to trastuzumab, new biomarkers of prognosis and prediction are warranted to allow a better patient stratification. Annexin A1 (ANXA1) was previously reported to contribute to trastuzumab resistance through AKT activation. An association between adenine thymine-rich interactive domain 1A (ARID1A) loss and ANXA1 upregulation was also previously suggested by others. Methods: in this study, we examined tissue samples from 215 HER-2+ breast cancer patients to investigate the value of ARID1A and ANXA1 protein levels in trastuzumab response prediction and patient outcome. Expression of ARID1A and ANXA1 were assessed by immunohistochemistry. Results: contrary to what was expected, no inverse association was found between ARID1A and ANXA1 expression. HER-2+ (non-luminal) tumours displayed higher ANXA1 expression than luminal B-like (HER-2+) tumours. Concerning trastuzumab resistance, ARID1A and ANXA1 proteins did not demonstrate predictive value as biomarkers. Nevertheless, an association was depicted between ANXA1 expression and breast cancer mortality and relapse. Conclusions: overall, our results suggest that ANXA1 may be a useful prognostic marker in HER-2+ patients. Additionally, its ability to discriminate between HER-2+ (non-luminal) and luminal B-like (HER-2+) patients might assist in patient stratification regarding treatment strategy. MDPI 2020-12-02 /pmc/articles/PMC7761245/ /pubmed/33276477 http://dx.doi.org/10.3390/jcm9123911 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Silva-Oliveira, Rita
Pereira, Filipa Ferreira
Petronilho, Sara
Martins, Ana Teresa
Lameirinhas, Ana
Constâncio, Vera
Caldas-Ribeiro, Inês
Salta, Sofia
Lopes, Paula
Antunes, Luís
Castro, Fernando
de Sousa, Susana Palma
Henrique, Rui
Jerónimo, Carmen
Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
title Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
title_full Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
title_fullStr Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
title_full_unstemmed Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
title_short Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
title_sort clinical significance of arid1a and anxa1 in her-2 positive breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761245/
https://www.ncbi.nlm.nih.gov/pubmed/33276477
http://dx.doi.org/10.3390/jcm9123911
work_keys_str_mv AT silvaoliveirarita clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT pereirafilipaferreira clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT petronilhosara clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT martinsanateresa clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT lameirinhasana clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT constanciovera clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT caldasribeiroines clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT saltasofia clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT lopespaula clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT antunesluis clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT castrofernando clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT desousasusanapalma clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT henriquerui clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer
AT jeronimocarmen clinicalsignificanceofarid1aandanxa1inher2positivebreastcancer